iCo grants option on non-ocular applications of bertilimumab
This article was originally published in Scrip
Executive Summary
iCo Therapeutics of Canada has granted Immune Pharmaceuticals an option to an exclusive licence for development and commercialisation rights to the systemic uses of iCo-008 (bertilimumab), iCo's human monoclonal antibody targeting eotaxin-1.